Zum Inhalt springen

Detailansicht

Covid-19, Remdesivir, Gilead Science and our Fund “ACATIS Aktien Global Fonds”

Kategorie: Blog Schweiz

by Eva Maria Zaragoza Laguarda, Institutional Sales

Our global equity fund “ACTIS Aktien Global Fonds”, for quite a while now, has been paying attention to companies that have a strong position in the fight against viruses or bacteria.

In that arena, one of those companies that investors can find in the portfolio is the US Group “Gilead Science Inc”, a research-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines.

The company researches and commercializes therapies, such as for HIV, hepatitis B + C and influenza and was involved, among other projects, in the development of Roche's world-leading influenza medicine "Tamiflu". Under Gilead Science we also find Remdesivir, it was its drug candidate to fight against Ebola, it also showed to be a candidate to work against SARS and MERS. Remdesivir appears to be an effective way to treat COVID-19 symptoms, the drug is in two Phase3 clinical studies for its evaluation.

EZ2645_zugeschnitten.jpg

Kontakt

Möchten Sie von uns automatisch auf dem neuesten Stand gehalten werden?

Dann füllen Sie bitte unser Kontaktformular aus und wir werden Sie in unseren Verteiler aufnehmen.